BIOALLIANCE PHARMA

The specialty pharma company hires a financial specialist with long experience at Pfizer as it prepares Loramyc® launch

Paris , November 21, 2006 -- BioAlliance Pharma SA (Euronext Paris – Code Isin : FR0010095596 - BIO), an emerging specialty pharmaceutical company, announced today the appointment of Nicolas Fellmann as Chief Financial Officer. Fellmann will play a key role in the growth of the company.

A graduate of the Lyon School of Management, Fellmann, 38, has more than 10 years experience in the pharmaceutical industry. His previous posts were as Director, treasury, tax and audit in the finance department of Pfizer France . He started his career with Ernst & Young, leaving in 1995 as Senior Financial Auditor.

“The arrival of Nicolas Fellmann marks a new turning point for BioAlliance Pharma,” said Dominique Costantini , MD, President and CEO of BioAlliance Pharma. “His experience of the pharmaceutical industry and his management abilities will be important assets as we address the challenges of fast growth and the launch and production of our medicines.”

The new CFO joins BioAlliance just after the company obtained a Marketing Authorization in France for its first product, Loramyc®, a treatment for oropharyngeal candidiasis in immuno-depressed patients. BioAlliance is already making preparations for the launch of this product, planned for early 2007. The company is continuing to move forward with its other research programs. Acyclovir Lauriad® and doxorubicin Transdrug® are being prepared for Phase II/III clinical trials.

About BioAlliance Pharma

BioAlliance Pharma SA (Euronext Paris: BIO) is an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections.

Specialty pharma targets the development and marketing of drugs for specialist markets and selected populations. This business model, unlike that of “big pharma” which targets general medicine, offers faster product development, lower R&D costs, smaller sales teams, and hence higher margins and fast growth.

The Company is developing three broad product ranges based on the Lauriad(R) adhesive technology which allows an early and prolonged release of therapeutic agents at the site of the disease, the Transdrug® nanoparticle technology designed specifically for intracellular targeting, and a New Chemical Entities program focused on development of new drugs in oncology and HIV.

The Loramyc(R) (miconazole Lauriad(R)) 50 mg Bioadhesive Buccal Tablet has completed two Phase III clinical trials in Europe for treatment of oropharyngeal candidiasis (OPC) in cancer and HIV patients. A pivotal Phase III trial of Loramyc(R) is ongoing in the US in 2006 for the same indication. A second product, acyclovir Lauriad(R), for the treatment of oral herpes, has completed a Phase I clinical trial in Europe. A Phase I/II trial in primary liver cancer (hepatocellular carcinoma or HCC) utilizing the Company's doxorubicin Transdrug® nanoparticle delivery technology has been completed in Europe, and has been granted orphan drug status by the EMEA and the FDA.

Disclaimer

This communication expressly or implicitly contains certain forward-lookingstatements concerning BioAlliance Pharma SA and its business. Such statementsinvolve certain known and unknown risks, uncertainties and other factors,which could cause the actual results, financial condition, performance or achievementsof BioAlliance Pharma SA to be materially different from any future results,performance or achievements expressed or implied by such forward-lookingstatements. BioAlliance Pharma SA is providing this communication as of thisdate and does not undertake to update any forward-looking statements containedherein as a result of new information, future events or otherwise.
Fora discussion of risks and uncertainties which could cause actual results, financialcondition, performance or achievements of BioAlliance Pharma SA to differ fromthose contained in the forward-looking statements please refer to the RiskFactors (Facteurs de Risque) section of the reference document approved bythe AMF on 28 April 2006 under the number R. 06-042, which is available onthe AMF website http://www.amf-france.org or BioAlliance Pharma S.A.'s website http://www.bioalliancepharma.com .